In-vivo dermal pharmacokinetics, efficacy, and safety of skin targeting nanoparticles for corticosteroid treatment of atopic dermatitis

International Journal of Pharmaceutics

Volumn 507, Issue 1-2, 2016, Pages 72-82

  Siddique, Muhammad Irfan ^a   Katas, Haliza ^a   Amin, Mohd Cairul Iqbal Mohd ^a   Ng, Shiow Fern ^a   Zulfakar, Mohd Hanif ^a   Jamil, Adawiyah ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Abbreviations AD atopic dermatitis; CSNPs chitosan nanoparticles; DPK dermal pharmacokinetics; HC hydrocortisone; HT hydroxytyrosol

Indexed keywords

CHITOSAN NANOPARTICLE; HYDROCORTISONE; HYDROXYTYROSOL; LIVER ENZYME; 3,4-DIHYDROXYPHENYLETHANOL; ANTIINFLAMMATORY AGENT; CHITOSAN; NANOPARTICLE; PHENETHYL ALCOHOL;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; ESCHERICHIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; RAT; SKIN ATROPHY; SKIN PENETRATION; SKIN TOXICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TOPICAL TREATMENT; YOUNG ADULT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DERMATITIS, ATOPIC; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PARTICLE SIZE; SKIN; SKIN ABSORPTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHITOSAN; DERMATITIS, ATOPIC; DRUG DELIVERY SYSTEMS; HYDROCORTISONE; NANOPARTICLES; PARTICLE SIZE; PHENYLETHYL ALCOHOL; RATS; SKIN; SKIN ABSORPTION;

EID: 84967144556     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.05.005     Document Type: Article

References (59)

1. T. Senyigit, F. Sonvico, S. Barbieri, Ö. Özer, P. Santi, and P. Colombo Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin J. Control. Release 142 2010 368 373
2. R. Alvarez-Román, A. Naik, Y.N. Kalia, R.H. Guy, and H. Fessi Skin penetration and distribution of polymeric nanoparticles J.Control. Release 99 2004 53 62
3. R.C. Andrews, and B.R. Walker Glucocorticoids and insulin resistance: old hormones new targets Clin. Sci. 96 1999 513 523
4. J. Arikawa, M. Ishibashi, M. Kawashima, Y. Takagi, Y. Ichikawa, and G. Imokawa Decreased levels of sphingosine a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus J. Invest. Dermatol. 119 2002 433 439
5. B. Baroli Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J. Pharm. Sci. 99 2010 21 50
6. G.M. Barratt Therapeutic applications of colloidal drug carriers Pharm. Sci. Technol. Today 3 2000 163 169
7. F. Benaouda, M.B. Brown, G.P. Martin, and S.A. Jones A study of simultaneoustriggered in situ drug supersaturation and hydrophilic matrix self-assembly Pharm. Res. 29 2012 3434 3442
8. N. Bhattarai, J. Gunn, and M. Zhang Chitosan-based hydrogels for controlled, localized drug delivery Adv. Drug Deliv. Rev. 62 2010 83 99
9. Atopic Dermatitis T. Bieber, and D.Y.M. Leung 2002 Marcel Dekker New York
10. Z. Bircan, M. Soran, I. Yildirim, M. Dogan, A. Sahin, A. Bilici, and M. Danaci The effect of alternate-day low dose prednisolone on bone age in children with steroid dependent nephrotic syndrome Int. Urol. Nephrol. 29 1997 357 361
11. M. Boguniewicz, and D.Y. Leung Atopic dermatitis: a disease of altered skin barrier and immune dysregulation Immunol. Rev. 242 2011 233 246
12. B. Brazzini, and N. Pimpinelli New and established topical corticosteroids in dermatology Am. J. Clin. Dermatol. 3 2002 47 58
13. R.V. Contri, T. Katzer, A.F. Ourique, A.L.M. da Silva, R.C. Beck, A.R. Pohlmann, and S.S. Guterres Combined effect of polymeric nanocapsules and chitosan hydrogel on the effect of capsaicinoids adhesion to the skin surface J. Biomed. Nanotechnol. 10 2014 725 743
14. M. Cristiani, D. Arrigo, M. Mandalari, G. Castelli, F.M.G. Sarpietro, and D. Micieli J. Agric. Food Chem. 55 2007 6300 6308
15. U. Darsow, J. Lubbe, A. Taieb, S. Seidenari, A. Wollenberg, A.M. Calza, F. Giusti, and J. Ring Position paper on diagnosis and treatment of atopic dermatitis J. Eur. Acad. Dermatol. Venereol. 19 2005 286 295
16. A.F. Davis, and J. Hadgraft Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate Int. J. Pharm. 76 1991 1 8
17. M. Fartasch, and T.L. Diepgen The barrier functions in atopic dry skin. Disturbance of membrane-coating granule exocytosis and formation of epidermal lipids Acta. Derm. Venereol. Suppl. 176 1992 26 31
18. M.I. Fernández-Mar, R. Mateos, M.C. García-Parrilla, B. Puertas, and E. Cantos-Villar Bioactive compounds in wine: resveratrol hydroxytyrosol and melatonin: a review Food Chem. 130 2012 797 813
19. A.J. Friedman, J. Phan, D.O. Schairer, J. Champer, M. Qin, A. Pirouz, K. Blecher-Paz, A. Oren, P.T. Liu, R.L. Modlin, and J. Kim Antimicrobial and anti-inflammatory activity of chitosan-alginate nanoparticles: a targeted therapy for cutaneous pathogens J. Investig. Dermatol. 133 2013 1231 1239
20. M. Furue, H. Terao, K. Rikishisa, K. Urabe, N. Kinukawa, Y. Nose, and T. Koga Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis Br. J. Dermatol. 148 2003 128 133
21. A.W. Hayes Guidelines for acute oral toxicity testing Principles and Methods of Toxicity 1989 Raven New York
22. U.R. Hengge, T. Ruzicka, R.A. Schwartz, and M.J. Cork Adverse effects of topical glucocorticosteroids J. Am. Acad. Dermatol. 54 2006 1 15
23. C. Herkenne, A. Naik, Y. Kalia, J. Hadgraft, and R. Guy Dermatopharmacoki-netic prediction of topical drug bioavailability in vivo J. Invest. Dermatol. 127 2007 887 894
24. C. Herkenne, I. Alberti, A. Naik, Y. Kalia, F. Mathy, V. Preat, and R.H. Guy In vivo methods for the assessment of topical drug bioavailability Pharm. Res. 25 2008 87 103
25. K.L.E. Hon, W.Y.C. Kan, and M.C.A. Lam CQLQ1, SCORAD and NESS: are they correlated? Qual. Life Res. 15 2006 1551 1558
26. D. Hühn, K. Kantner, C. Geidel, S. Brandholt, I. De Cock, S.J. Soenen, and W.J. Parak Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge ACS Nano 7 2013 3253 3263
27. J. Hughes, and M. Rustin Corticosteroids Clin. Dermatol. 15 1997 715 721
28. Z. Hussain, H. Katas, M.C.I.M. Amin, E. Kumolosasi, F. Buang, and S. Sahudin Self-assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone/hydroxytyrosol: an ex vivo and in vivo study using an NC/Nga mouse model Int. J. Pharm. 444 2013 109 119
29. J.M. Jensen, S. Pfeiffer, M. Witt, M. Brautigam, C. Neumann, M. Weichenthal, T. Schwarz, R. Folster- Holst, and E. Proksch Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis J. Allergy Clin. Immunol. 124 2009 19 28
30. H.E. Junginger, and J.C. Verhoef Macromolecules as safe penetration enhancers for hydrophilic drugs - a fiction? PSTT1 1998 370 376
31. M. Kalariya, B.K. Padhi, M. Chougule, and A. Misra Clobetasol propionate solid lipid nanoparticles cream for effective treatment if eczema: formulation and clinical implications Indian J. Exp. Biol. 43 2005 233 240
32. L. Keawchaoon, and Y. Rangrong Preparation, characterization and in vitro release study of carvacrol-loaded chitosan nanoparticles Colloids Surf. B 84 2011 163 171
33. A. Kubo, K. Nagao, and M. Amagai Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases J. Clin. Invest. 122 2012 440 447
34. S. Kuchler, M.R. Radowski, T. Blaschke, M. Dathe, J. Plendl, R. Haag, M. Schäfer-Korting, and K.D. Kramer Nanoparticles for skin penetration enhancement: a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles Eur. J. Pharm. Biopharm. 71 2009 243 250
35. T.K. LaPier GC-induced muscle atrophy. The role of exercise in treatment and prevention J. Cardiopulm. Rehabil. 17 1997 76 84
36. J. Lademann, H. Richter, A. Teichmann, N. Otberg, U. Blume-Peytavi, J. Luengo, B. Weib, U.F. Schaefer, C.M. Lehr, R. Wepf, and W. Sterry Nanoparticles - an efficient carrier for drug delivery into the hair follicles Eur. J. Pharm. Biopharm. 66 2007 159 164
37. D.Y.M. Leung, M. Boguniewicz, M.D. Howell, I. Nomura, and Q.A. Hamid New insights into atopic dermatitis J. Clin. Invest. 113 2004 651 657
38. M.L. Marchiori, G. Lubini, G. Dalla Nora, R.B. Friedrich, M.C. Fontana, A.F. Ourique, M.O. Bastos, L.A. Rigo, C.B. Silva, S.B. Tedesco, and R.C.R. Beck Hydrogel containing dexamethasone-loaded nanocapsules for cutaneous administration: preparation, characterization and in vitro drug release study Drug Dev. Ind. Pharm. 36 2010 962 971
39. NCCLS - National Committee for Clinical Laboratory Standards Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, NCCLS Document M7-A5, National Committee for Clinical Laboratory Standards, Wayne, PA, 2000.
40. Y. Nakamura, J.K.B. Oscherwitz, S.M. Cease, R. Chan, M. Munoz-Planillo, A.E. Hasegawa, G.Y. Villaruz, M.J. Cheung, McGavin, and M. Otto Staphylococcus d-toxin promotes allergic skin disease by inducing mast cell degranulation Nature 503 2013 397 401
41. I. Nomura, E. Goleva, M.D. Howell, Q.A. Hamid, P.Y. Ong, C.F. Hall, M.A. Darst, B. Gao, M. Boguniewicz, J.B. Travers, and D. Leung Cytokine milieu of atopic dermatitis as compared to psoriasis, skin prevents induction of innate immune response genes J. Immunol. 171 2003 3262 3269
42. OECD Repeated dose dermal toxicity: 21/28 day study OECD Guidelines for Testing of Chemicals, No. 410 1981 Organization for Economic Cooperation and Development Paris, France
43. P. Pérez, A. Page, A. Brano, M. Del Rio, I. Giménez-Conti, I. Budunova, T.J. Slaga, and J.L. Jorcano Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor FASEB J. 15 2001 2030 2032
44. L.K. Pershing, L.D. Lambert, V.P. Shah, and S.Y. Lam Variability and correlation of chromameter and tape stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans Int. J. Pharm. 86 1992 201 210
45. L.K. Pershing, B.S. Silver, G.G. Krueger, V.P. Shah, and J.P. Skelly Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching assay Pharm.Res. 9 1992 45 51
46. T.W. Prow, J.E. Grice, L.L. Lin, R. Faye, M. Butler, W. Becker, M.T.W. Elisabeth, and M.S. Robert Nanoparticles and microparticles for skin drug delivery Adv. Drug Deliv. Rev. 63 2011 470 491
47. T. Rhen, and J.A. Cidlowski Antiinflammatory action of glucocorticoids -new mechanisms of old drugs N. Engl. J. Med. 353 2005 1711 1723
48. A. Sarwar, K. Haliza, and M.Z. Noraziah Antibacterial effects of chitosan-tripolyphosphate nanoparticles: impact of particle size molecular weight J. Nanopart. Res. 16 2014 1 14
49. S. Scalia, E. Franceschinis, D. Bertelli, and V. Iannuccelli Comparative evaluation of the effect of permeation enhancers, lipid nanoparticles and colloidal silica on in vivo human skin penetration of quercetin Skin Pharmacol. Physiol. 26 2013 57 67
50. T. Senyigit, C. Padula, Ö. Özer, and P. Santi Different approaches for improving skin accumulation of topical corticosteroids Int. J. Pharm. 380 2009 155 160
51. K.A. Shah, A.A. Date, M.D. Joshi, and V.B. Patravale Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery Int. J. Pharm. 345 2007 163 171
52. T.E. Shaw, G.P. Currie, C.W. Koudelka, and E.L. Simpson Eczema prevalence in the United States: data from the 2003 national survey of children's health J. Invest. Dermatol. 131 2011 67 73
53. G. Silvestrini, P. Ballanti, F.R. Patacchioli, P. Mocetti, R. Di Grezia, B. Wedard, L. Angelucci, and E. Bonucci Evaluation of apoptosis and the GC receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-dose treatment with corticosterone Bone 26 2000 33 42
54. T. Takai, and S. Ikeda Barrier dysfunction caused by environmental proteases in the pathogenesis of allergic diseases Allergol. Int. 60 2011 25 35
55. Q. Tan, W. Liu, C. Guo, and G. Zhai Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery Int. J. Nanomed. 6 2011 1621
56. B.A. van den Bergh, J.A. Bouwstra, H.E. Junginger, and P.W. Wertz Elasticity of vesicles affects hairless mouse skin structure and permeability J. Control. Release 62 1999 367 379
57. L.A. Van Boxtel, P.L. Hardus, W.S. Al Hassan, P.C. van Voorst Vader, and N.M. Jansonium Corticosteroids and the risk of glaucoma Nederlands tijdschrift voor geneeskunde 149 2005 2485 2489
58. M.J. Wolfsegger, and T. Jaki Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs J. Pharmacokinet. Pharmacodyn. 36 2009 479 494
59. V. Ziogas, G. Tanou, A. Molassiotis, and G. Diamantidis Antioxidant and free radical-scavenging activities of phenolic extracts of olive fruits Food Chem. 120 2010 1097 1103